Zevalin Y-90 and Cytopenia
Result of checking the interaction of drug Zevalin Y-90 and disease Cytopenia for safety when used together.
When checking interaction based on authoritative sources Drugs.com, Rxlist.com, Webmd.com, Medscape.com there are contraindications or side effects that may cause harm or increase the negative effect from drug use in presence of concomitant diseases.
Consumer:The use of ibritumomab tiuxetan may result in severe and prolonged cytopenias. Do not administer the ibritumomab tiuxetan therapeutic regimen to patients with >= 25% lymphoma marrow involvement and/or impaired bone marrow reserve. It is recommended to monitor patients for signs of cytopenia for up to 3 months after treatment and for hematological toxicity including development of myelodysplastic syndrome and/or acute myelogenous leukemia.
Generic Name: ibritumomab
Brand Name: Y-90 Zevalin, In-111 Zevalin
Synonyms: Y-90 Zevalin
Zevalin Y-90 - cytopenia 
Zevalin Y-90 - citopenia 
Zevalin Y-90 - sitopenia 
Zevalin Y-90 - sitopenia 
Zevalin Y-90 - citopenia 
Zevalin Y-90 - cytopénie 
Zevalin Y-90 - Zytopenie 
Zevalin Y-90 - citopenia 
Zevalin Y-90 - цитопения 
Zevalin Y-90 - sitopeni 
Zevalin Y-90 - قلة الكريات البيض 
Zevalin Y-90 - 血细胞减少症